Board of Directors & Advisory Board

Brian Bosse has been a respected professional investor for nearly 30 years with corporate capital allocation policy being his key business specialty. He forms and motivates great teams revolve around stakeholder return on investment using leadership styles that fuel employee intellectual curiosity. Formerly Brian served Dundee Corporation’s Goodman & Company Investment Counsel as portfolio manager of the Goodman Bluespring Fund. He earned an honors degree from the Lazaridis School of Business and Economics in Waterloo Ontario plus the Chartered Financial Analyst designation. Brian joined Zentek in May 2018 as director and officer following a successful proxy battle.

Joseph Armand Korkis is a board-certified Otolaryngologist and Head and Neck surgeon. Dr Korkis is a graduate of the Royal College of Surgeons in Ireland and spend 9 years in post graduate studies in Ireland and Canada. He is the assistant Clinical Professor in the department of Otolaryngology and Head and Neck surgery at McMaster University. He was a founder of the residency program of Otolaryngology surgery along with Head and Neck surgery at McMaster University and is involved in the undergraduate and postgraduate MD training programs at McMaster.

Kenneth Reed, M.D. is a board certified dermatologist in private practice and serves as a scientific advisor to several innovative biotechnology companies. After completing a residency at the Harvard-MGH combined dermatology program, he established a clinical practice in a Boston suburb, DermAsap, and has continued as a principle investigator for a number of biopharmaceutical companies. He currently serves on the board of directors of Red Hill Biopharma and Minerva Biotechnologies. Dr. Reed is also a cofounder of Early Cell, a company focused on early detection of circulating fetal cells, and Lispiro LLC, which focuses on idiopathic pulmonary fibrosis, and age related disorders.

Yingfu Li is a Professor in the Department of Biochemistry and Biomedical Sciences at McMaster University. He earned a PhD in Biochemistry from Simon Fraser University in 1997, where he discovered a DNA molecule that catalyzes porphyrin metalation, which won him Governor General Academic Gold Medal and Natural Sciences and Engineering Research Council of Canada Doctoral Prize, both in 1998. He was awarded a Medical Research Council of Canada postdoctoral fellow in 1999 and carried out his postdoctoral research at Yale University between 1997-1999, where he studied a series of catalytic DNA molecules for DNA phosphorylation, DNA capping and DNA ligation. In November 1999, he joined McMaster University as an Assistant Professor in the Department of Biochemistry and Biomedical Sciences, was promoted to Associate Professor in 2005 and Full Professor in 2010. At McMaster, he has established a research group focusing on artificial nucleic acid molecules with catalytic and/or binding properties. He has published extensively in the fields of chemistry, biochemistry and molecular evolution of nucleic acids, including over 200 research and review articles, over 20 book chapters, 1 book. He has filed over 30 patents on functional nucleic acids and diagnostic tests. He has also served as an Associate Editor of Journal of Molecular Evolution and as a member of editorial board of Scientific Reports, and Analysis and Sensing. He has received several recognitions, including Canada Research Chair, New Investigator Award from the Canadian Institute of Health Research, Premier Research Excellent Award from Ontario Government, McBryde Medal from Canadian Society of Chemistry.

Mr. Kaza graduated from The Wharton School of the University of Pennsylvania with a BS in Finance Summa Cum Laude at age 19 and has spent the last 25 years consistently focused on disruptive technologies. He started his career in Silicon Valley at a prominent investment banking group founded by Frank Quattrone where he worked on numerous transactions involving companies such as Amazon, Apple, Northern Telcom, and Lam Research. Mr. Kaza then entered the money management business as a Vice President at Pequot Capital Management, at the time one of the world’s largest alternative asset managers with a focus on technology investing. He was then hired by Stanley Druckenmiller as a Managing Director at Duquesne Capital Management to focus primarily on technology investing.

In 2003, Mr. Kaza founded Seasons Capital Management, which he helped grow into a multi-billion-dollar alternative investment manager that oversaw several technology-related investment strategies. In 2010, Mr. Kaza shifted his focus to running primarily internal capital with a continued primary focus on disruptive technologies. Consistent with this focus, Mr. Kaza was introduced to the Zentek management team during the Summer of 2021, when he became a shareholder.